TITLE:
Evaluation of Two Serological Screening Kits for Hepatitis C Virus Infection at the Regional Blood Transfusion Center of Ouagadougou, Burkina Faso
AUTHORS:
Arzouma Paul Yooda, Koumpingnin Nebie, Juliette Tranchot-Diallo, Salam Sawadogo, Moutanou Modeste Judes Zeye, Abdoul-Guaniyi Sawadogo, Abdou Azaque Zoure, Dinanibè Kambire, Serge Sawadogo, Seimbou Zalla, Yetema Dieudonné Yonli, Abibou Simpore, Sibiri Nana, Ashmed Chèickh Bachirou Nana, Anita Pierrette Siritie, Fiffou Yougbare, Sonia Ba-Nébhane Sontie, Alain Konseybo, Jean Etienne Koanda, Oury Sanou, Jacques Simpore
KEYWORDS:
HCV, Sensitivity, Specificity, Burkina Faso
JOURNAL NAME:
Advances in Infectious Diseases,
Vol.10 No.5,
November
2,
2020
ABSTRACT: Introduction: In Burkina Faso, screening for hepatitis C virus in blood donations is made using sensitive ELISA (Enzyme Linked Immuno Sorbent Assay) type kits. However, no confirmation of the positive results obtained with these kits is made before their notification to the blood donors due to the high costs of the confirmation kits of immunoblots type. Objective: Evaluate two rapid kits against one immunoblot kit in order to determine the most efficiency which will be proposed as an alternative for the confirmation of ELISA tests in the socio-economic context of Burkina Faso. Material and Methods: The study was carried out using a panel of 72 sera, of which 22 were positive for anti-HCV antibodies and 50 were negative. The sera were tested using the Monolisa® HCV Ag-Ab ULTRA kit and confirmed with the DECISCAN HCV Plus kit. The panel was then tested with the SD BIOLINE HCV kit and the HCV TRI-DOT kit and the results obtained were evaluated against those of the DECISCAN HCV Plus kit used as “gold standard”. Results: Compared to the DECISCAN HCV Plus kit, the HCV TRI-DOT kit exhibited a sensitivity and specificity of 100% and the SD BIOLINE HCV kit a sensitivity of 86.36% and a specificity of 100%. Conclusion: Based on the results recorded by the HCV TRI-DOT kit, it would be best suited to the sero-epidemiological context of blood donors from the National Blood Transfusion Center and could be proposed as an alternative for confirmation of ELISA tests.